Last updated: July 31, 2026
XOPENEX HFA is the branded levalbuterol tartrate metered-dose inhaler for acute treatment and prevention of bronchospasm in patients with reversible obstructive airway disease. The product has no active late-stage clinical development program, no meaningful new indication strategy, and limited remaining commercial differentiation. Its market position has weakened because generic levalbuterol inhalation aerosol is available and albuterol remains the dominant short-acting beta2 agonist.
XOPENEX HFA’s commercial outlook is mature to declining. Future value depends mainly on residual brand prescribing, formulary placement, supply continuity and physician preference rather than patent exclusivity or clinical innovation.
What is XOPENEX HFA and how does it work?
XOPENEX HFA contains levalbuterol tartrate, the R-enantiomer of racemic albuterol. It is a short-acting beta2-adrenergic agonist delivered through a hydrofluoroalkane metered-dose inhaler.
Each actuation delivers 45 micrograms of levalbuterol tartrate from the actuator mouthpiece, equivalent to 41 micrograms of levalbuterol. The labeled dose for adults and adolescents is two inhalations every four to six hours, with some patients responding to one inhalation. The product is indicated for patients aged four years and older with reversible obstructive airway disease, including asthma-related bronchospasm.[1]
The pharmacologic rationale for levalbuterol was reduced exposure to the S-enantiomer found in racemic albuterol. In clinical practice, however, the therapeutic differentiation has been limited. Albuterol is less expensive, widely available and embedded in asthma treatment guidelines and payer formularies.
XOPENEX HFA product profile
| Attribute |
XOPENEX HFA |
| Active ingredient |
Levalbuterol tartrate |
| Drug class |
Short-acting beta2-adrenergic agonist |
| Dosage form |
HFA metered-dose inhaler |
| Strength |
45 mcg per actuation |
| Route |
Oral inhalation |
| Primary use |
Acute treatment and prevention of bronchospasm |
| FDA application |
NDA 021730 |
| Original FDA approval |
2005 |
| Pediatric labeling |
Patients aged 4 years and older |
| Reference product status |
Reference listed drug for generic development |
| Current development stage |
Commercial product; no active innovation-stage program identified |
What clinical trials support XOPENEX HFA?
The clinical evidence for XOPENEX HFA is established rather than expanding. The FDA approval package relied on studies evaluating pulmonary function, bronchodilator response, dose selection and safety in adults, adolescents and children with reversible obstructive airway disease.[1]
The HFA formulation was developed as a replacement for the earlier chlorofluorocarbon-containing XOPENEX inhaler following the phaseout of ozone-depleting CFC propellants. The HFA product was assessed for dose delivery, clinical performance and safety under the FDA’s CFC transition framework.
Are there active clinical trials for XOPENEX HFA?
No active late-stage or registration-directed clinical program is associated with XOPENEX HFA. The product’s clinical-development profile is mature:
| Clinical objective |
Status |
| Initial approval |
Completed |
| HFA propellant transition |
Completed |
| Dose and delivery evaluation |
Completed |
| Pediatric efficacy and safety |
Completed |
| New indication development |
No active program identified |
| Combination-product development |
No active program identified |
| Outcomes or comparative-effectiveness expansion |
No active program identified |
ClinicalTrials.gov contains studies involving levalbuterol and asthma, but these should not be treated as evidence of an active XOPENEX HFA lifecycle program unless the study specifically identifies the branded HFA product and a sponsoring company.[2]
The main clinical risk is not failed efficacy. It is substitution by generic levalbuterol and albuterol products with similar treatment roles.
When does XOPENEX HFA lose exclusivity?
XOPENEX HFA has passed its primary period of market exclusivity. The product was approved in 2005, and its commercial protection has been affected by the expiration of relevant patent rights, pediatric exclusivity periods and generic competition.
The critical distinction is between patent expiry and practical market exclusivity. A product can remain commercially available after patent expiry, but its pricing power declines once an FDA-approved generic can be substituted.
What is the Orange Book status of XOPENEX HFA?
The FDA Orange Book identifies approved drug products, therapeutic-equivalence evaluations and applicable patent or exclusivity information. XOPENEX HFA should be analyzed through the NDA 021730 listing and the FDA’s current Orange Book database rather than through historical patent summaries.[3]
The relevant commercial conclusion is that XOPENEX HFA is no longer protected by a current, enforceable exclusivity position that prevents generic levalbuterol HFA competition. Any historical patents associated with the product do not create a durable barrier to generic entry today.
| Exclusivity factor |
XOPENEX HFA assessment |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
Expired |
| Core product patent barrier |
No longer commercially blocking |
| Current generic competition |
Present |
| Orange Book relevance |
Primarily historical and litigation-related |
| Remaining protection |
Possible residual formulation, device or labeling rights, subject to current FDA records |
Which companies are challenging XOPENEX HFA?
Generic competition has replaced traditional Paragraph IV risk as the principal market issue. The important competitors are manufacturers of levalbuterol tartrate inhalation aerosol and manufacturers of albuterol HFA inhalers.
Potential generic entrants use an Abbreviated New Drug Application pathway and must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA’s product-specific requirements. For a metered-dose inhaler, the regulatory burden includes device performance, emitted dose, aerodynamic particle-size distribution, formulation characteristics and manufacturing controls.
What Paragraph IV risks affected XOPENEX HFA?
Historical Paragraph IV challenges may have involved patents listed for the levalbuterol inhalation aerosol product. The commercial effect of those challenges depended on the timing of ANDA filing, patent litigation, 30-month stays and the scope of any settlement.
The current business issue is different. Generic levalbuterol products have reached the market, and the brand cannot rely on an unchallenged patent position to preserve price or volume. A new Paragraph IV event would be material only if it involved a later patent covering a specific device, formulation or manufacturing feature and if the patent had enough remaining term to delay additional competition.
What formulations are protected by XOPENEX HFA?
XOPENEX HFA’s key technical elements are the levalbuterol tartrate formulation, HFA propellant system, metered-dose valve, actuator and container-closure system. These elements can be protected separately through formulation, device, manufacturing or method-of-use claims.
In practice, formulation patents are most valuable when they create a measurable performance advantage or are difficult to design around. For XOPENEX HFA, the mature product platform and availability of generic HFA levalbuterol indicate that the principal formulation barrier has been overcome.
Are manufacturing and device patents still a barrier?
Manufacturing complexity remains relevant even after patent expiry. HFA inhalers require control of:
- Delivered-dose uniformity
- Valve metering performance
- Particle-size distribution
- Suspension stability
- Canister and actuator compatibility
- Extractables and leachables
- Microbial and particulate specifications
- Long-term stability
These requirements can delay generic approval or limit the number of qualified suppliers. They do not, however, create brand-level exclusivity once FDA-approved generic products are available.
How strong is the XOPENEX HFA patent estate?
The patent estate is commercially weak relative to an active, single-source branded inhaler. Its strongest historical assets were likely directed to the inhalation formulation, propellant delivery system and product-specific use. Those rights no longer provide a reliable basis for premium pricing.
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
Not commercially relevant for the mature product |
| HFA formulation protection |
Historical value; limited current blocking power |
| Device protection |
Potentially relevant to specific designs, but generally design-aroundable |
| Method-of-use protection |
Limited practical value in a crowded rescue-bronchodilator market |
| Manufacturing protection |
Can affect generic execution but rarely preserves brand exclusivity alone |
| Litigation leverage |
Low to moderate, depending on any unexpired listed patents |
| Overall estate strength |
Low for long-term commercial defense |
What is the FDA regulatory status of XOPENEX HFA?
XOPENEX HFA is an FDA-approved prescription inhalation aerosol. Its label covers treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, including asthma.[1]
The FDA label warns about paradoxical bronchospasm, cardiovascular effects, hypokalemia, hypoglycemia and hypersensitivity reactions. Common adverse reactions include palpitations, tachycardia, headache, dizziness and tremor. These risks are consistent with the beta2-agonist class.
XOPENEX HFA is not a maintenance controller therapy. It does not replace inhaled corticosteroids or other long-term asthma-control medicines. The product is used for rapid symptom relief and prevention of exercise- or exposure-related bronchospasm.
How does XOPENEX HFA compare with albuterol HFA?
Albuterol HFA has the stronger commercial position. It has broader manufacturer participation, greater formulary familiarity and lower generic pricing.
| Factor |
XOPENEX HFA |
Albuterol HFA |
| Active ingredient |
Levalbuterol |
Racemic albuterol |
| Clinical role |
Rescue bronchodilator |
Rescue bronchodilator |
| Generic availability |
Yes |
Extensive |
| Payer position |
More restricted in many plans |
Preferred in many plans |
| Differentiation |
R-enantiomer formulation |
Established standard of care |
| Pricing power |
Low |
Low to moderate for branded products |
| Clinical-development activity |
Limited |
Limited for mature products |
| Substitution risk |
High |
High, but market volume is larger |
XOPENEX HFA can retain use among patients who experience tolerability concerns with racemic albuterol or whose clinicians prefer levalbuterol. That segment is unlikely to support substantial growth without new evidence, a differentiated device or a contracting advantage.
What is the XOPENEX HFA market size and revenue exposure?
Public company disclosures generally do not provide a current standalone revenue line for XOPENEX HFA. Historical revenue should therefore not be confused with current product sales, and prescription volume should not be treated as net manufacturer revenue.
The relevant market is the short-acting rescue inhaler segment, which includes:
- Generic albuterol HFA
- Branded albuterol products
- Generic levalbuterol HFA
- Nebulized albuterol and levalbuterol
- Other short-acting bronchodilator delivery formats
XOPENEX HFA’s addressable market is narrower than the total rescue-inhaler market because levalbuterol is a minority alternative to albuterol. Its revenue exposure is concentrated in residual branded prescriptions, selected commercial plans and patients whose prescribers maintain levalbuterol-specific treatment.
What is the market projection for XOPENEX HFA?
The base-case projection is continued volume erosion and low-single-digit or negative annual revenue growth, with price pressure exceeding any increase in respiratory-disease prevalence. The product does not have a credible path to sustained growth based on its current label.
| Scenario |
2025-2030 outlook |
Main driver |
| Downside |
Rapid decline toward niche residual sales |
Formulary exclusion and generic substitution |
| Base case |
Continued low-to-mid single-digit annual volume decline |
Mature demand and limited differentiation |
| Upside |
Stabilization, not major growth |
Supply reliability, contracting or targeted prescriber retention |
An aging population and persistent asthma prevalence support demand for rescue bronchodilators generally. Those factors benefit the category, not necessarily XOPENEX HFA. Generic substitution captures much of the category growth.
What patent litigation and settlement risks affect XOPENEX HFA?
The principal litigation risk is limited. A new dispute would most likely involve:
- A patent listed for the reference product.
- A device or formulation patent asserted against an ANDA filer.
- A manufacturing patent involving aerosol suspension or dose delivery.
- A trademark or trade-dress dispute after generic entry.
Historical settlements could have delayed generic launch or established licensed-entry dates. Their economic effect diminishes after the agreed entry date and does not restore the original brand monopoly.
No current litigation event has been identified that materially changes the established generic-entry outlook for XOPENEX HFA.
What generic launch scenarios exist for XOPENEX HFA?
Generic launch has already altered the product’s economics. The remaining scenarios are:
- Continued generic price competition with declining branded share.
- Additional generic entrants reducing wholesale acquisition cost.
- Brand withdrawal from selected channels.
- Retention of a small medically preferred or prescriber-directed segment.
- Manufacturer licensing or authorized-generic arrangements to preserve limited volume.
The largest barrier for new entrants is technical execution, not patent validity. Inhaler manufacturing capacity, FDA review, device comparability and supply-chain reliability determine whether a filed ANDA becomes a durable commercial competitor.
Key Takeaways
- XOPENEX HFA is an established levalbuterol tartrate HFA rescue inhaler with FDA approval under NDA 021730.
- Its clinical-development program is complete, with no active late-stage lifecycle strategy identified.
- Core exclusivity has expired, and generic levalbuterol HFA competition is established.
- The Orange Book and historical patent record remain relevant for legal diligence, but they do not support a strong current blocking position.
- Albuterol HFA has greater market scale, lower cost and stronger payer preference.
- XOPENEX HFA’s base-case outlook is declining volume, limited pricing power and residual niche demand.
- Manufacturing and device controls remain technical barriers for entrants, but they do not recreate brand exclusivity.
- Revenue exposure is difficult to quantify because current standalone brand sales are not consistently disclosed by public companies.
FAQs About XOPENEX HFA Patent and Market Outlook
Is XOPENEX HFA still available?
Availability depends on manufacturer distribution, pharmacy inventory and payer coverage. FDA approval does not guarantee continuous commercial distribution.
Is there a generic version of XOPENEX HFA?
Yes. Generic levalbuterol tartrate inhalation aerosol products compete with the branded HFA inhaler.
Does XOPENEX HFA have longer patent protection than albuterol?
No commercially meaningful patent advantage remains for XOPENEX HFA over generic albuterol or generic levalbuterol.
Can a new levalbuterol inhaler still obtain FDA approval?
Yes. A manufacturer can pursue an ANDA or other applicable FDA pathway, but it must satisfy inhaler-specific equivalence, device and manufacturing requirements.
Will XOPENEX HFA sales increase as asthma prevalence rises?
Category demand may rise, but generic substitution and payer preference make sustained growth for the branded product unlikely without a new commercial or clinical differentiator.
References
- U.S. Food and Drug Administration. (2017). Xopenex HFA (levalbuterol tartrate) inhalation aerosol prescribing information.
- National Library of Medicine. (n.d.). ClinicalTrials.gov: Levalbuterol studies. https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
